What brexpiprazole brings to the treatments for schizophrenia in pediatric patients

Glecaprevir/pibrentasvir was a "highly efficacious treatment for people with acute HCV," with 96.2% of patients analyzed having sustained virological response 12 weeks post-treatment.

The final episode in our podcast series on atypical anorexia discusses fat bias in health care and its impact on diagnosis and when pushback against diagnosis happens.

The phase 2 trial will be 4 weeks and evaluate investigational, once-daily roflumilast cream 0.05% in infants 3 months to less than 2 years of age.

Dr. Erin Harrop discusses the necessity of understanding that eating disorders do not all look the same in every patient and how a multidisciplinary approach could be an effective way to diagnose and manage anorexia nervosa that is atypical.

Results at 24 weeks revealed that 76% of individuals achieved a 75% or more improvement in overall disease severity (EASI-75), trial's primary endpoint.

The combination therapy yielded boosted treatment benefits of navepegritide, including improvement in mean ACH Z-score and mean annualized growth.